The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Queen Elizabeth II Health Sciences Centre

Status and phase: Unknown; Phase 4

Conditions: Pertussis

Treatments: Biological: Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)

Study type: Interventional

Funder types: Other

Identifiers

NCT00336115

qeii

Details and patient eligibility

About

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18-64
• BMT at the QEII Health Sciences Centre
• BMT within last 12 months
• Able to read and write English language
• Able to give consent

Exclusion criteria

• Active infection
• Active GVHD
• Recent IVIG
• Allergy to components of vaccine
• Diphtheria or tetanus vaccination within 18 months

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)